Arcellx

Arcellx EBIT per Share

Delisted

The EBIT per Share of Arcellx (ACLX) as of Nov 20, 2026 is -4.49 USD. In the previous year, EBIT per Share was -2.56 USD — a change of 75.43% (lower).

EBIT per Share

-4.49USD

YoY

75.43%

Last updated:

EBIT per Share of Arcellx is 2025 -4.49 USD. EBIT per Share of Arcellx was 2024 -2.56 USD. It decreases by 75.43% lower compared to the previous year.

The Arcellx EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-1.72 USD
Jan 1, 2024
-2.56 USD
Jan 1, 2025
-4.49 USD
Jan 1, 2026 (e)
-0.15 USD
Jan 1, 2027 (e)
-0.53 USD
Jan 1, 2028 (e)
-0.90 USD
Jan 1, 2029 (e)
-1.49 USD
Jan 1, 2030 (e)
-2.17 USD
The Arcellx EBIT per Share history
YEAREBIT per ShareYoY
est-2.17USD+45.50%
est-1.49USD+66.46%
est-0.90USD+70.51%
est-0.53USD+256.77%
est-0.15USD-96.72%
-4.49USD+75.43%
-2.56USD+49.03%
-1.72USD-60.35%
-4.34USD+123.72%
-1.94USD+31.51%
-1.47USD+185.21%
-0.52USD-98.97%
-50.18USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

EBIT per Share of Arcellx is -4.49 USD in 2025.

EBIT per Share of Arcellx changed from -2.56 USD to -4.49 USD, representing a 75.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Arcellx since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Arcellx

All Key Metrics — Arcellx